Have you evaluated the performance of Exelixis' (EXEL) international operations for the quarter ending December 2025? Given the extensive global presence of this drug developer, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For inve ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with ...

Core Insights - Exelixis, Inc. (EXEL) reported better-than-expected fourth-quarter results for 2025, with adjusted earnings per share (EPS) of 94 cents, surpassing the Zacks Consensus Estimate of 77 cents and up from 55 cents in the same quarter last year [1][2][6] - The company achieved net revenues of $598.7 million, exceeding the Zacks Consensus Estimate of $585 million, representing a year-over-year increase of 5.6% [2][4] - Despite the positive results, Exelixis' stock experienced a decline in pre-market trading following the earnings announcement [2] Financial Performance - The growth in net revenues was primarily driven by higher product sales, with net product revenues reaching $546.6 million, a 6% increase year over year [4] - Cabometyx (cabozantinib) generated revenues of $544.7 million, slightly missing the Zacks Consensus Estimate of $554 million but marginally exceeding internal estimates [5][6] - Collaboration revenues totaled $52.1 million, reflecting a 1% year-over-year increase, mainly due to higher royalty revenues from cabozantinib sales outside the U.S. [8] Operating Expenses - Research and development expenses, including stock-based compensation, decreased by 14.4% year over year to $213.2 million, attributed to lower clinical trial costs [9] - Selling, general, and administrative expenses fell by 8% year over year to $123 million, primarily due to reductions in stock-based compensation and personnel costs [9] Share Repurchase Program - During the quarter, Exelixis repurchased $264.5 million in shares, completing a $500 million share repurchase program authorized in February 2025 [10] - Since the initiation of its first share repurchase program in March 2023, the company has repurchased a total of $2.16 billion in common stock [10] 2025 Results and 2026 Guidance - For 2025, Exelixis reported revenues of approximately $2.32 billion, a 7% increase from 2024, with adjusted EPS of $3.08, up from $2 in 2024 [11] - The company expects total revenues for 2026 to be between $2.525 billion and $2.625 billion, with net product revenues projected to be in the range of $2.325 billion to $2.425 billion [12] Pipeline and Regulatory Updates - Exelixis is developing zanzalintinib, a next-generation oral investigational tyrosine kinase inhibitor, with an NDA accepted by the FDA for previously treated metastatic colorectal cancer [14][15] - The company is also advancing several phase I assets and has two new investigational new drug filings planned for 2026 [21][22] Market Position and Future Outlook - Cabometyx remains a leading TKI monotherapy for renal cell carcinoma (RCC) and is gaining traction in the neuroendocrine tumor market [23] - The strong uptake of Cabometyx in the newly approved NET indication is expected to drive future sales growth [24] - The potential approval of zanzalintinib is viewed as a significant catalyst for Exelixis' oncology pipeline, with management expanding sales infrastructure to support growth [24][25]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Exelixis reported $598.66 million in revenue for Q4 2025, a 5.6% year-over-year increase, with an EPS of $0.94 compared to $0.55 a year ago, exceeding both revenue and EPS estimates [1][4] Revenue Performance - Net product revenues reached $546.58 million, surpassing the average estimate of $529.04 million by nine analysts, reflecting a 6.1% increase year-over-year [4] - Collaboration revenues were reported at $52.09 million, exceeding the average estimate of $49.91 million, marking a significant year-over-year increase of 2289.3% [4] - CABOMETYX generated $544.7 million in net product revenues, slightly below the average estimate of $554.08 million, but still showing a 6.2% year-over-year growth [4] - COMETRIQ reported net product revenues of $1.8 million, which fell short of the average estimate of $3.15 million, indicating a year-over-year decline of 25.6% [4] - License revenues from collaboration reached $66.36 million, exceeding the average estimate of $48.87 million from five analysts [4] Stock Performance - Exelixis shares have returned -0.3% over the past month, while the Zacks S&P 500 composite remained unchanged [3] - The stock holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

分组1 - Exelixis reported quarterly earnings of $0.94 per share, exceeding the Zacks Consensus Estimate of $0.77 per share, and showing an increase from $0.55 per share a year ago, resulting in an earnings surprise of +22.25% [1] - The company achieved revenues of $598.66 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.39% and increasing from $566.76 million year-over-year [2] - Exelixis has consistently surpassed consensus EPS estimates over the last four quarters, achieving this four times [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.76 on revenues of $618.11 million, while for the current fiscal year, the estimate is $3.39 on revenues of $2.57 billion [7] - The Medical - Biomedical and Genetics industry, to which Exelixis belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were approximately $599 million, including cabozantinib franchise net product revenues of $546.6 million [16] - Full year 2025 US CABO franchise net product revenues grew 17% to approximately $2.12 billion compared to 2024 [10] - GAAP net income for Q4 2025 was approximately $244.5 million, or $0.92 per share basic [18] - Non-GAAP net income for Q4 2025 was approximately $259.5 million, or $0.97 per share basic [19] - Total operating expenses for Q4 2025 were approximately $363 million, up from $341 million in Q3 2025 [18] Business Line Data and Key Metrics Changes - CABOMETYX maintained its position as the leading TKI for renal cell carcinoma (RCC) and neuroendocrine tumors, with a TRX volume growth of 15% in Q4 2025 compared to Q4 2024 [21][22] - CABOMETYX's market share in the oral TKI market increased from 43% to 46% from Q4 2024 to Q4 2025 [21] - The company is preparing to launch zanzalintinib, with a focus on accelerating growth in the GI franchise [11][24] Market Data and Key Metrics Changes - CABOMETYX's US net product revenues exceeded $100 million for the neuroendocrine tumor indication in 2025 [10] - The market basket growth rate for oral TKIs was 7% for the same period, while CABOMETYX outpaced this growth [22] - The company anticipates significant growth opportunities in the community setting for CABOMETYX [52] Company Strategy and Development Direction - The company aims to build a multi-franchise business in solid tumor oncology, focusing on cabozantinib and zanzalintinib [8] - The strategy includes expanding leadership in gastrointestinal (GI) indications and enhancing the commercial footprint for both CABOMETYX and ZANZA [9][11] - Business development activities are focused on late-stage assets in GU and GI spaces, with a commitment to disciplined investment in high-value opportunities [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026 being a transformational year, with expectations to build on the momentum from 2025 [7][36] - The company is focused on maximizing productivity and advancing its early-stage pipeline while preparing for the potential launch of zanzalintinib [27][36] - Management highlighted the importance of addressing unmet medical needs in the colorectal cancer market with the upcoming STELLAR-303 trial results [25][29] Other Important Information - The company repurchased $954 million of its outstanding common stock in 2025, with approximately $590 million remaining under the stock repurchase plan [19][20] - The gross-to-net for the cabozantinib franchise in Q4 2025 was 28.5%, lower than in Q3 2025, primarily due to lower PHS and 340B volume [16] Q&A Session Summary Question: Duration of small manufacturer discount for Zanza and share repurchase cadence - Management indicated that the small manufacturer exemptions are tied to having a single product as the majority revenue source, which is expected to remain for the foreseeable future [40] - The company plans to continue share repurchases as long as shares are perceived as undervalued, with a commitment to complete the current authorization [41] Question: 340B purchasing behavior and Part D redesign impact - Management noted variability in 340B purchasing behavior and expects this to continue, which could impact gross-to-net [43][44] - The company will design its channel for Zanza to optimize results based on past experiences with CABO [45] Question: STELLAR-316 population size and timeline - The estimated population for STELLAR-316 is approximately 20,000-25,000 patients who are MRD positive after definitive therapy [48] Question: Revenue potential for neuroendocrine tumors - Management expressed confidence in the growth potential for CABOMETYX in neuroendocrine tumors, particularly in the community setting [51][52] Question: Zanza trial design and market expectations - Management emphasized the importance of establishing Zanza as a standard of care in RCC and highlighted ongoing discussions for potential combination trials [56][57] Question: Non-clear cell RCC market size and competition - Non-clear cell RCC represents approximately 20% of the RCC market, and the company sees significant potential for growth in this underserved area [83]

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were approximately $599 million, with cabozantinib franchise net product revenues of $546.6 million, and CABOMETYX net product revenues at $544.7 million [15][18] - Gross-to-net for the cabozantinib franchise in Q4 2025 was 28.5%, lower than the previous quarter, primarily due to lower PHS and 340B volume [15][16] - GAAP net income for Q4 2025 was approximately $244.5 million, or $0.92 per share basic, and $0.88 per share diluted [17] - Non-GAAP net income was approximately $259.5 million, or $0.97 per share basic, and $0.94 per share diluted [18] - Cash and marketable securities at year-end 2025 were approximately $1.66 billion, with $954 million spent on share repurchases during the fiscal year [18][19] Business Line Data and Key Metrics Changes - The cabozantinib business maintained strong performance, with U.S. CABO franchise net product revenues growing 17% to approximately $2.12 billion for the full year 2025 [10] - CABOMETYX continued to be the leading TKI for renal cell carcinoma (RCC) and the market leader for neuroendocrine tumors in the oral second-line-plus segment [20] - CABOMETYX TRX volume grew 15% in Q4 2025 compared to Q4 2024, outpacing the market basket growth rate of 7% [21] Market Data and Key Metrics Changes - CABOMETYX's market share in the oral TKI market increased from 43% to 46% from Q4 2024 to Q4 2025 [20] - CABOMETYX revenue in neuroendocrine tumors exceeded $100 million in 2025, indicating strong market demand [23] Company Strategy and Development Direction - The company aims to build a multi-franchise business in solid tumor oncology, focusing on cabozantinib and zanzalintinib, with a strategy that encompasses products, tumor indications, and modalities [8][9] - The company is preparing for the potential launch of zanzalintinib in colorectal cancer (CRC) and has expedited the build-out of its GI sales team to support this initiative [11][23] - Business development activities are focused on late-stage assets in GU and GI spaces, with an emphasis on pay-for-success transactions [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026 being a transformational year, with expectations for continued growth in cabozantinib and the potential launch of zanzalintinib [35] - The company is actively engaging with regulators regarding the NDA for zanzalintinib, with a PDUFA target action date set for December 3, 2026 [26][28] Other Important Information - The company reported a sequential increase in operating expenses due to higher manufacturing costs, NDA filing fees, and personnel expenses [16][17] - The company has approximately $590 million remaining under its stock repurchase plan authorized in October 2025 [19] Q&A Session Summary Question: Duration of small manufacturer discount for Zanza and share repurchase cadence - Management indicated that the small manufacturer exemptions are tied to having a single product as the majority revenue source, which is expected to remain for the foreseeable future [39] - Share repurchases will continue as long as the company feels undervalued, with a commitment to complete the remaining authorization this year [40] Question: 340B purchasing behavior and Part D redesign impact - Management noted variability in 340B purchasing behavior and expects this to continue, which could impact gross-to-net [42] - The company plans to optimize its channel for Zanza based on experiences from cabozantinib [44] Question: STELLAR-316 population size and timeline - The estimated population for STELLAR-316 is around 20,000-25,000 patients who are MRD positive after definitive therapy [47] Question: Revenue potential for NET and market dynamics - Management expressed confidence in the growth potential for neuroendocrine tumors, emphasizing the importance of community outreach and the expansion of the GI sales team [51] Question: Non-clear cell RCC market size and outcomes - Non-clear cell RCC represents approximately 20% of RCC, and the company is optimistic about the potential benefits of its pivotal study in this underserved population [82]

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were approximately $599 million, including cabozantinib franchise net product revenues of $546.6 million [13] - Full year 2025 US CABO franchise net product revenues grew 17% to approximately $2.12 billion compared to 2024 [7] - GAAP net income for Q4 2025 was approximately $244.5 million, or $0.92 per share basic [16] - Non-GAAP net income for Q4 2025 was approximately $259.5 million, or $0.97 per share basic [17] - Cash and marketable securities at the end of 2025 were approximately $1.66 billion [17] Business Line Data and Key Metrics Changes - CABOMETYX maintained its position as the leading TKI for renal cell carcinoma (RCC) and neuroendocrine tumors, with Q4 2025 TRX volume growing 15% compared to Q4 2024 [19][20] - CABOMETYX's gross-to-net for Q4 2025 was 28.5%, lower than the previous quarter due to lower PHS and 340B volume [13] - Zanzalintinib is positioned as the next potential oncology franchise, with seven ongoing pivotal trials [10][24] Market Data and Key Metrics Changes - CABOMETYX's market share in the oral TKI segment grew from 43% to 46% from Q4 2024 to Q4 2025 [19] - The market basket growth rate for oral TKIs was 7% during the same period, indicating CABOMETYX outpaced the market [20] - The neuroendocrine tumor indication for CABOMETYX exceeded $100 million in revenue for 2025 [21] Company Strategy and Development Direction - The company aims to build a multi-franchise business in solid tumor oncology, focusing on cabozantinib and zanzalintinib [5][6] - The strategy includes expanding leadership in gastrointestinal (GI) indications while maintaining a strong position in genitourinary (GU) oncology [5] - Business development activities are focused on late-stage assets in GU and GI spaces, with a priority on pay-for-success transactions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in building on the momentum from 2025 into 2026, with expectations for continued strong performance from the cabozantinib business [5] - The company is preparing for the potential launch of zanzalintinib, with a PDUFA date set for later in the year [22] - Management highlighted the significant unmet medical need in the third-line plus colorectal cancer setting, which zanzalintinib aims to address [22][26] Other Important Information - The company repurchased $954 million of its common stock in 2025, retiring approximately 24 million shares [17] - The remaining balance under the stock repurchase plan is approximately $590 million [18] Q&A Session Summary Question: How long will the company benefit from the small manufacturer discount for Zanza? - Management indicated that the small manufacturer exemptions are tied to having a single product as the majority revenue source, which is expected to remain the case for the foreseeable future [34][35] Question: Can you comment on recent 340B purchasing behavior? - Management noted variability in 340B purchasing behavior throughout 2025 and expects continued variability in 2026, which could impact gross-to-net [39][40] Question: What is the expected population size for STELLAR-316? - The estimated population for STELLAR-316 is around 20,000-25,000 patients who are MRD positive after definitive therapy [42][43] Question: What is the growth expectation for NET revenues? - Management expressed optimism about the growth potential in the neuroendocrine tumor segment, emphasizing the need to expand outreach in the community setting [45][47] Question: How does the company anticipate positive data impacting commercial strategy? - Positive data from ongoing trials is expected to enhance communication with physicians and clarify the benefits of the treatment for patients [56][58]

TUESDAY, FEBRUARY 10, 2026 Fourth Quarter & Fiscal Year 2025 Financial Results Nasdaq: EXEL Today's Agenda Introduction Business Update & Highlights Financial Results & Guidance Commercial Update Research & Development Update Andrew Peters SVP, Strategy and Investor Relations Michael M. Morrissey, Ph.D. President and CEO Chris Senner EVP and CFO PJ Haley EVP, Commercial Dana T. Aftab, Ph.D. EVP, Research and Development All Participants 2 Q&A Forward-Looking Statements This presentation, including any oral ...